Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Regeneron Pharmaceuticals, Inc. (REGN) P/S ratio
As of 25 September 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a P/S ratio of 5.2×. Over the past ten years it has ranged from 3.5× (June 2022) to 18.0× (June 2015); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 11.5× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 5.6× | 4.01% |
| FY2024 | 5.4× | (26.48%) |
| FY2023 | 7.4× | 16.13% |
| FY2022 | 6.3× | 52.62% |
| FY2021 | 4.2× | (32.11%) |
| FY2020 | 6.1× | (2.16%) |
| FY2019 | 6.3× | (20.17%) |
| FY2018 | 7.8× | 13.08% |
| FY2017 | 6.9× | (15.32%) |
| FY2016 | 8.2× | (40.01%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 4.1× | (23.39%) |
| Mar 2026 | 5.4× | (4.32%) |
| Dec 2025 | 5.6× | 37.68% |
| Sep 2025 | 4.1× | 5.32% |
| 42 more quarters | Free account |
Against its own ten years
Low 3.5×
High 18.0×
Ten-year median
6.7×
Current reading's percentile
19
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | 5.2× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.6× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 7.1× |
| RPRX Royalty Pharma PLC compare | 10.2× |
| VRTX Vertex Pharmaceuticals Incorporated compare | 10.6× |
| ARGX argenex SE compare | 11.2× |
| INSM Insmed, Inc. compare | 22.5× |
| MRNA Moderna, Inc. compare | 35.5× |
| RVMD Revolution Medicines, Inc. compare | 1,606× |
| Biotechnology industry median | 11.5× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on REGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement